Lexaria director gifts 100,000 shares back to company

Lexaria Bioscience Corp. director Christopher Bunka reported a bona fide gift of 100,000 common shares back to Lexaria, which were returned to the company’s treasury.

Rhea-AI Filing Summary

Lexaria Bioscience Corp. director Christopher Bunka reported a bona fide gift of 100,000 common shares back to Lexaria, which were returned to the company’s treasury. This was not an open‑market sale and carried no stated share price.

After the gift, Bunka holds 273,543 common shares directly and 281,912 common shares indirectly through a private holding company as of the reported date. He also retains multiple stock option awards over additional common shares, with exercise prices between 1.0400 and 3.0000 per share and expirations from 2026 through 2030.

Insider Trade Summary

100,000 shares gifted

Gift 10 txns

Insider BUNKA CHRISTOPHER

Role Director

Type	Security	Shares	Price	Value
Gift	common shares	100,000	$0.00	$0.00
holding	Stock Options	--	--	--
holding	Stock Options	--	--	--
holding	Stock Options	--	--	--
holding	Stock Options	--	--	--
holding	Stock Options	--	--	--
holding	Stock Options	--	--	--
holding	Stock Options	--	--	--
holding	common shares	--	--	--
holding	common shares	--	--	--

Holdings After Transaction: common shares — 647,086 shares (Direct); Stock Options — 184,834 contracts (Direct); common shares — 281,912 shares (Indirect, Private Holding Company)

Footnotes (1)

1. F1. The 100,000 shares were gifted back to Lexaria Bioscience Corp. and returned to treasury.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Christopher Bunka report for Lexaria Bioscience (LEXX)?

Christopher Bunka reported a bona fide gift of 100,000 Lexaria common shares back to the company, which were returned to treasury. This Form 4 shows a non-market transfer, not an open-market trade, and updates his direct and indirect share ownership.

How many Lexaria Bioscience (LEXX) shares were gifted and where did they go?

The filing shows 100,000 Lexaria common shares were gifted back to Lexaria Bioscience Corp. itself and returned to the company’s treasury. This reduces Bunka’s direct holdings while effectively moving those shares from public ownership back onto the corporate balance sheet.

Did Christopher Bunka sell Lexaria (LEXX) shares on the open market in this Form 4?

No open-market sale is reported. The Form 4 records a bona fide gift of 100,000 common shares back to Lexaria, returned to treasury, at a stated price of $0.00 per share. It reflects a non-cash transfer rather than a market sale or purchase.

What are Christopher Bunka’s Lexaria (LEXX) shareholdings after this reported gift?

After the gift, Bunka holds 273,543 Lexaria common shares directly. He also has 281,912 common shares held indirectly through a private holding company. These figures are reported as total shares following the transactions on the Form 4’s non-derivative ownership tables.

What Lexaria (LEXX) stock options does Christopher Bunka still hold according to this filing?

The filing lists several stock option awards over Lexaria common shares, with exercise prices between $1.0400 and $3.0000 per share. These options have stated expiration dates ranging from 2026 through 2030 and represent additional potential equity exposure beyond his current shareholdings.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/18/2026 - 11:37 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BUNKA CHRISTOPHER

(Last) (First) (Middle)

SUITE 100

740 MCCURDY ROAD

(Street)

KELOWNA V1X 2P7

(City) (State) (Zip)

BRITISH COLUMBIA, CANADA

(Country)

2. Issuer Name and Ticker or Trading Symbol
Lexaria Bioscience Corp. [ LEXX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
common shares								373,543	D
common shares								281,912	I	Private Holding Company
common shares	03/17/2026		G		100,000(1)	D	$0	273,543	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options	$3							04/26/2021	04/26/2026	Common Shares	26,000		26,000	D
Stock Options	$3							06/08/2021	06/08/2026	Common Shares	23,334		49,334	D
Stock Options	$3							09/01/2021	09/01/2026	Common Shares	15,000		64,334	D
Stock Options	$2.91							08/29/2022	08/29/2027	Common Shares	30,000		94,334	D
Stock Options	$1.15							10/26/2023	10/26/2028	Common Shares	30,000		124,334	D
Stock Options	$2.36							04/26/2024	04/26/2029	Common Shares	49,500		173,834	D
Stock Options	$1.04							05/15/2025	05/15/2030	Common Shares	11,000		184,834	D

Explanation of Responses:

1. The 100,000 shares were gifted back to Lexaria Bioscience Corp. and returned to treasury.

	/Chris Bunka/	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)